Moderna
- Country
- ๐บ๐ธUnited States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company...
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
- Conditions
- Interventions
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 310
- Registration Number
- NCT05743881
- Locations
- ๐บ๐ธ
Los Angeles Children's Hospital, Los Angeles, California, United States
๐บ๐ธPalmetto Pediatrics, PA, North Charleston, South Carolina, United States
๐ฟ๐ฆFamily Centre for Research with Ubuntu (FAMCRU)- Tygerberg, Cape Town, Western Cape, South Africa
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults โฅ50 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 659
- Registration Number
- NCT05701800
- Locations
- ๐บ๐ธ
Velocity Clinical Research - Westlake, Los Angeles, California, United States
๐บ๐ธTekton Research, Inc - Longmont Center, Longmont, Colorado, United States
๐บ๐ธMeridien Research, Lakeland, Florida, United States
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.
- Conditions
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT05683457
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT05659264
- Locations
- ๐บ๐ธ
Jacksonville Center For Clinical Research - ERN - PPDS, Jacksonville, Florida, United States
๐บ๐ธTennessee Center for Clinical Trials, Tullahoma, Tennessee, United States
๐ต๐ฑUniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Podlaskie, Poland
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 325
- Registration Number
- NCT05606965
- Locations
- ๐บ๐ธ
Washington University in St. Louis, Saint Louis, Missouri, United States
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
- Conditions
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 392
- Registration Number
- NCT05585632
- Locations
- ๐บ๐ธ
Centricity Research, Columbus, Georgia, United States
๐ฆ๐บParatus Clinical Research Brisbane, Albion, Queensland, Australia
๐ฆ๐บParatus Clinical Research Western Sydney, Blacktown, New South Wales, Australia
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
- Conditions
- Interventions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 700
- Registration Number
- NCT05584202
- Locations
- ๐บ๐ธ
South Texas Clinical Research - Corpus Christi, Corpus Christi, Texas, United States
๐บ๐ธCedar Health Research - Dedicated Research Facility, Dallas, Texas, United States
๐บ๐ธEclipse Clinical Research, Tucson, Arizona, United States
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 770
- Registration Number
- NCT05575492
- Locations
- ๐จ๐ฆ
Bluewater Clinical Research Group, Sarnia, Ontario, Canada
๐จ๐ฆCentre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada
๐ฌ๐งAddenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study
- Conditions
- Interventions
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 11010
- Registration Number
- NCT05572658
- Locations
- ๐บ๐ธ
Tekton Research - Longmont - Platinum - PPDS, Longmont, Colorado, United States
๐บ๐ธSeattle Womens: Health, Research, Gynecology, Seattle, Washington, United States
๐บ๐ธHope Research Institute LLC - Hunt - PPDS, Tempe, Arizona, United States
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
- Conditions
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 22510
- Registration Number
- NCT05566639
- Locations
- ๐บ๐ธ
Velocity Clinical Research - Westlake, Los Angeles, California, United States
๐บ๐ธCCT Research, Las Vegas, Nevada, United States
๐บ๐ธSouth Florida Research Center, Inc., Miami, Florida, United States